South Korean biopharmaceutical company Celltrion will invest nearly $330 million to acquire Eli Lilly's factory in New Jersey, USA.

South Korean biopharmaceutical company Celltrion announced on September 23 that it has signed an agreement to acquire a biologics manufacturing plant owned by Eli Lilly located in Branchburg, New Jersey, USA, for nearly 330 million US dollars. It is expected that Celltrion will invest at least 1.4 trillion Korean won in the acquisition and expansion of the plant.